LACTOLOGY FOUNDATION

The drugs in ATC class A03AE04 are serotonin 5‑HT4 receptor agonists used as enterokinetic agents for chronic constipation, with prucalopride as the representative compound; overall toxicity is low, but gastrointestinal and neurological adverse effects are common, and lactation use is possible with caution when first‑line laxatives have failed.medpedia.framar+4

Pharmacological class overview

ATC A03AE04 belongs to “drugs acting on serotonin receptors” within medicines for functional gastrointestinal disorders, and historically coded prucalopride in this subgroup before reclassification to A06AX05.drugbank+2
Prucalopride is a dihydrobenzofuran‑based, highly selective serotonin 5‑HT4 receptor agonist with strong prokinetic activity in the gastrointestinal tract, accelerating colonic transit and improving bowel movements in chronic idiopathic constipation (CIC).^drugs.ncats+3
Selectivity for 5‑HT4 over other serotonin or cardiac ion‑channel targets reduces the risk of cardiotoxicity seen with earlier non‑selective 5‑HT4 agonists such as cisapride and tegaserod.pmc.ncbi.nlm.nih+3

Indications and therapeutic use

Prucalopride is indicated for adults with chronic idiopathic constipation in whom conventional laxatives of different classes, used at maximal recommended doses for months, have failed to provide adequate relief.sps+3
It is approved in the European Union and other regions as a second‑line agent for CIC, typically in women but also in men, reflecting updated labeling compared with earlier “women‑only” indications.europa+3
The standard oral dose in adults with normal renal function is 2 mg once daily, reduced to 1 mg once daily in severe renal impairment to limit systemic exposure.droracle+3

Toxicology and safety profile

General toxicity

Prucalopride shows a favorable overall safety profile, with most adverse effects being dose‑dependent, reversible, and related to its prokinetic action.medpedia.framar+3
The most frequently reported adverse reactions are headache, dizziness, palpitations, nausea, diarrhea, abdominal pain, fatigue, and pyrexia, generally occurring early in therapy and often resolving within the first week.jdc.jefferson+4
In clinical trials and post‑marketing studies, serious systemic toxicity has been uncommon, and prucalopride does not appear to significantly affect laboratory safety parameters at therapeutic doses.gastroenterologyadvisor+2

Cardiovascular safety

Prucalopride has been extensively evaluated for cardiovascular (CV) risk because earlier 5‑HT4 agonists were associated with QT prolongation and ischemic events.pmc.ncbi.nlm.nih+2
Across phase 3 studies and a large real‑world cohort (>35,000 patients), prucalopride did not increase rates of major adverse cardiovascular events compared with polyethylene glycol, with an incidence rate ratio around 0.64 and no concerning trends in blood pressure, ECG parameters, or QTc prolongation.pubmed.ncbi.nlm.nih+2
Preclinical in‑vitro and in‑vivo data similarly show no clinically significant binding to cardiac ion channels and no major cardiotoxicity signals at exposures exceeding human therapeutic levels.cellagentech+3

Gastrointestinal and neurological adverse effects

The prokinetic action leads to dose‑related diarrhea, abdominal cramps, and occasionally vomiting, which are usually mild‑to‑moderate but may cause dehydration in susceptible patients.drugbank+3
Headache and dizziness are among the most common neurological adverse effects, likely related to central or systemic serotonergic modulation; they rarely necessitate discontinuation but warrant patient counseling, especially in the first days of treatment.jdc.jefferson+3
There is no convincing evidence of long‑term neurotoxicity, but data on very prolonged use (>5 years) are limited, so regular clinical review of benefit–risk is advisable in chronic therapy.gastroenterologyadvisor+2

Contraindications and cautions

Prucalopride is contraindicated in patients with known hypersensitivity to the drug, intestinal perforation or obstruction, and severe inflammatory bowel disease, where enhanced motility could aggravate pathology.europa+2
Use requires caution in severe renal impairment, where dose reduction is mandated, and in severe hepatic disease due to possible changes in drug handling and comorbidity‑related risks.droracle+3
Given limited data in children and adolescents, prucalopride is generally restricted to adults, and careful monitoring is needed when off‑label pediatric use is contemplated.clinicaltrials.ucsd+2

Lactation (breastfeeding) considerations

Pharmacokinetics in lactation

Prucalopride is orally available and minimally protein‑bound, and it is excreted into breast milk, with a reported milk‑to‑plasma AUC ratio about 2.65:1 in lactating women receiving 2 mg daily.sps+1
The estimated infant daily dose via milk is approximately 1.7 mcg/kg, corresponding to about 6% of the maternal weight‑adjusted dose, a level generally below the usual 10% threshold of concern for many drugs.droracle
Ongoing observational research is specifically measuring prucalopride concentrations in human milk and monitoring growth and development of breastfed infants exposed to maternal therapy, which should improve future risk assessment.clinicaltrials.ucsd

Clinical recommendations during breastfeeding

Specialist lactation guidance suggests that prucalopride may be used with caution in breastfeeding when first‑line measures (dietary fiber, osmotic laxatives such as lactulose or polyethylene glycol, and bulk‑forming agents) have failed.gpnotebook+2
Other laxatives are generally preferred because most are minimally absorbed, leading to negligible breast‑milk levels, but the low relative infant dose of prucalopride can be acceptable when maternal clinical need is high and constipation is refractory.gpnotebook+2
When prucalopride is used, the infant should be monitored for changes in stool pattern (especially diarrhea), feeding behavior, weight gain, and signs of gastrointestinal distress, while unnecessary interruption of breastfeeding should be avoided.sps+1

Maternal risk–benefit during lactation

The developmental and health benefits of breastfeeding must be weighed against the mother’s need for effective treatment of chronic constipation and the low but present infant exposure to prucalopride.sps+1
Standard adult dosing (2 mg once daily, or 1 mg daily in severe renal impairment) is usually maintained, as dose reduction may compromise efficacy without substantially changing milk transfer ratios.drugbank+2
From a toxico‑lactological perspective, prucalopride represents a reasonable second‑line option in breastfeeding women with CIC, provided that non‑pharmacological and conventional laxative strategies have been exhausted and that shared decision‑making is documented.gpnotebook+3

Drug interactions and clinical monitoring

Prucalopride has limited clinically significant pharmacokinetic interactions because it is only partially metabolized and is largely excreted unchanged in urine and feces.europa+1
However, co‑administration with drugs that themselves prolong QTc or cause electrolyte disturbances (for example, certain diuretics or antiarrhythmics) calls for ECG and clinical monitoring, even though prucalopride alone has not shown meaningful QT effects.pubmed.ncbi.nlm.nih+3
In lactating women, concurrent use of other serotonergic agents or prokinetics should be carefully reviewed to avoid additive gastrointestinal or neurological adverse effects in both mother and infant.drugbank+2

Sections

1.     Introduction
Prucalopride is a highly selective serotonin 5‑HT4 receptor agonist originally classified under ATC A03AE04 as a drug acting on serotonin receptors for functional gastrointestinal disorders.medpedia.framar+2
It is used as a second‑line enterokinetic agent in adults with chronic idiopathic constipation when conventional laxatives have failed to provide adequate relief.medpedia.framar+2

2.     Mechanism of action
Prucalopride stimulates 5‑HT4 receptors on enteric neurons, enhancing colonic motility, increasing high‑amplitude propagated contractions, and accelerating whole‑gut transit time.mayoclinic.elsevierpure+2
Its high selectivity reduces off‑target serotonergic and cardiac ion‑channel interactions, distinguishing it from earlier 5‑HT4 agonists with less favorable safety profiles.drugs.ncats+3

3.     Indications, dosing, and contraindications
Indicated for adults with chronic idiopathic constipation refractory to other laxatives, prucalopride is usually given orally at 2 mg once daily, with 1 mg once daily in severe renal impairment.europa+3
It is contraindicated in patients with hypersensitivity, intestinal perforation or obstruction, and severe inflammatory bowel disease, and should be used cautiously in significant renal or hepatic dysfunction.medpedia.framar+2

4.     Adverse effects and toxicology
Common adverse reactions include headache, dizziness, palpitations, nausea, diarrhea, abdominal pain, fatigue, and pyrexia, most often transient and mild‑to‑moderate.jdc.jefferson+4
Large clinical and observational datasets show no evidence of increased major adverse cardiovascular events or clinically relevant QTc prolongation compared with non‑absorbed laxatives.pubmed.ncbi.nlm.nih+2

5.     Use in pregnancy
Human pregnancy data are limited; prucalopride should therefore be avoided unless potential maternal benefits outweigh potential unknown fetal risks and alternative treatments are inadequate.drugbank+1
If used, clinicians should document justification and consider specialist consultation in obstetrics and gastroenterology.

6.     Lactation (breastfeeding)
Prucalopride is excreted into breast milk with a milk‑to‑plasma AUC ratio around 2.65, but the estimated infant dose via milk is only about 6% of the maternal weight‑adjusted dose.droracle+1
Specialist sources recommend that prucalopride may be used with caution during breastfeeding, generally after failure of first‑line laxatives, with monitoring of the infant for diarrhea, feeding changes, and growth.clinicaltrials.ucsd+3

7.     Interactions and monitoring
Clinically relevant pharmacokinetic interactions are uncommon, but careful review is required when combining prucalopride with QT‑prolonging drugs or agents that disturb electrolytes.gastroenterologyadvisor+3
In lactating women, concurrent serotonergic medications and other prokinetics should be evaluated to avoid additive adverse effects and to maintain overall benefit–risk balance.sps+2

8.     Summary for clinical practice
Prucalopride (ATC A06AX05, historically A03AE04) is a modern enterokinetic laxative with a favorable cardiovascular safety profile and predictable gastrointestinal adverse effects.jdc.jefferson+4
In breastfeeding, cautious second‑line use is acceptable in selected women with refractory constipation, provided infant monitoring is arranged and standard non‑absorbed laxatives have been tried or are unsuitable.gpnotebook+3